Location Directory

Clinical trials in Dallas, Texas

This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13791

Shown on this page

Current sort

Institutions in Dallas

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UT Southwestern Medical Center

Live official records

Open in full search

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more

Conditions: Pulmonary Embolism
Interventions: FlowTriever System, Anticoagulation Agents; Device · Drug
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 42
States / cities: Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: Pasritamig, Docetaxel, Prednisone/Prednisolone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 65
States / cities: Chandler, Arizona • Little Rock, Arkansas • Springdale, Arkansas + 57 more

Conditions: Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions: EYP-1901, Aflibercept (2.0 mg); Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 53
States / cities: Bakersfield, California • Encino, California • Glendale, California + 49 more

Conditions: Valvular Heart Disease Patients, Aortic Stenosis, Mitral Regurgitation, Left Ventricular Diastolic Dysfunction
Interventions: Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.); Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 65 Years to 85 Years
Enrollment: 1,088 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Multiple Myeloma
Interventions: JNJ-79635322, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 35 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation); Drug · Radiation
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 60
States / cities: Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more

Conditions: Multiple Myeloma
Interventions: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 49
States / cities: Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Bryant, Arkansas • Bellflower, California • Glendale, California + 31 more

Conditions: Healthy
Interventions: LY3867070, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Anaheim, California • Dallas, Texas

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Androgen Deprivation Therapy (ADT), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 2,517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 44
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 36 more

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Molgramostim, Placebo, Molgramostim Open-label; Drug
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more

Clinical trials in Dallas, Texas

Filter and sort this location

Institutions in Dallas

Live official records

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

The PEERLESS II Study

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

A Study of LY3867070 in Healthy Participants

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)